School of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Department of Dermatology, Baylor College of Medicine, Houston, Texas, USA.
Pediatr Dermatol. 2022 Jul;39(4):646-647. doi: 10.1111/pde.14959. Epub 2022 Jul 27.
Selumetinib is a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor (MEKi) approved to treat inoperable plexiform neurofibromas and used off-label for low-grade gliomas. Acneiform eruptions are a known complication of MEKi use, and in some cases, may lead to paused, dose-reduced, or discontinued therapy. Isotretinoin has been reported as an effective treatment for acneiform eruptions secondary to targeted therapies, primarily in the adult population. Here we describe a pediatric patient with a severe acneiform eruption secondary to selumetinib who was successfully treated with low-dose isotretinoin when unresponsive to conventional therapies.
色瑞替尼是一种丝裂原活化蛋白激酶/细胞外信号调节激酶抑制剂（MEKi），被批准用于治疗不可手术的丛状神经纤维瘤，并被用于治疗低级别的神经胶质瘤。痤疮样皮疹是 MEKi 使用的已知并发症，在某些情况下，可能导致暂停、减少剂量或停止治疗。异维 A 酸已被报道为治疗靶向治疗引起的痤疮样皮疹的有效方法，主要用于成年人群。在这里，我们描述了一名儿童患者，由于色瑞替尼而出现严重的痤疮样皮疹，在常规治疗无效后，低剂量异维 A 酸治疗成功。
